Category: Sponsors

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2017

SHARE THIS POST TORONTO, ONTARIO–(Marketwired – Oct. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals sectors, today announced its results for the fiscal year ended June 30, 2017. The Audited Financial Statements and Management’s Discussion and Analysis for the year ended June 30, 2017, may be viewed on SEDAR at www.sedar.com. “I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year,” said Craig Leon, Chief Executive Officer of Revive. “The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities.” Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially...

Read More

Emerald Health’s Two Cannabis Production Expansion Sites Progressing for Legalized Adult-Use Market in 2018

SHARE THIS POST Emerald submits applications to Health Canada for two significant production expansion projects, including one of Canada’s largest-scale greenhouse operations Victoria, BC, October 18, 2017 – Emerald Health Therapeutics Inc. (“EHT”) (TSXV: EMH; OTCQX: EMHTF), through Emerald Health Botanicals Inc. (“Emerald”), its wholly owned subsidiary and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), has submitted license applications to Health Canada for approval of two new growing sites. Emerald is preparing for the large-scale production of cannabis in anticipation of legalization of the adult-use cannabis market on July 1, 2018. In September, Emerald filed an application to Health Canada for its Pure Sunfarms’ Delta, BC facility, which is a partnership with Village Farms (TSXV: VFF). This partnership combines Emerald’s extensive medical cannabis growing experience and broad portfolio of cannabis genetics with Village Farms’ many decades of greenhouse growing expertise and large-scale, quality, low-cost production of an array of plant products and a currently producing, highly efficient 25-acre, 1.1 million square feet greenhouse facility. Emerald and Village Farms are retrofitting this greenhouse from tomato growing into a configuration optimized for largescale cannabis cultivation. With a key goal of the partnership to be a large, very low-cost cannabis producer, Pure Sunfarms also optioned from Village Farms an additional 3.7 million square feet of existing highly efficient greenhouse space in the same Delta complex. In...

Read More

Supreme Pharmaceuticals Announces Upsize of Previously Announced Bought Deal Private Placement to $35 Million

SHARE THIS POST October 18, 2017 Download this Press Release PDF Format (opens in new window) /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ TSXV: FIRE TORONTO, Oct. 18, 2017 /CNW/ – Supreme Pharmaceuticals Inc. (the “Company”) (TSXV:FIRE) announced today that it has amended its agreement with Canaccord Genuity Corp., as lead underwriter on behalf of a syndicate of underwriters (the “Underwriters”), to increase the size of its previously announced bought deal private placement of convertible debenture units (the “Convertible Debenture Units”) to $35,000,000. Under the terms of the amending agreement, the underwriters will now have an option to acquire up to 5,250 additional Convertible Debenture Units, each having the same terms as the Convertible Debenture Units above, which option is exercisable until the Closing Date (as hereinafter defined).  All other previously announced terms of the Offering (as hereinafter defined) remain unchanged. As previously announced, each Convertible Debenture Unit will consist of $1,000 principal amount of 8.0% senior unsecured convertible debentures (the “Convertible Debentures”) and 313 common share purchase warrants (the “Warrants”) of the Company (the “Offering”). The Convertible Debentures will bear interest from the date of closing at 8.0% per annum, payable annually in arrears on December 30, 2018 and thereafter semi-annually on the last day of June and December in each year and will mature two years following the closing of the Offering (the...

Read More

MYM Enters Partnership to Build one Million Square Foot Cannabis Production Facility in Australia

SHARE THIS POST October 18, 2017 |In News |By cris UNCODE.initHeader(); MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF) (the “Company” or “MYM”) is pleased to announce that it has entered into a strategic partnership with PUF Ventures Inc. (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF) (“PUF”) for the construction of a one million square foot greenhouse facility in northern New South Wales Australia called the Northern Rivers Project. The Northern Rivers Project is a partnership with the Richmond Valley Council—the local government in New South Wales, Australia—and PUF Ventures Australia (“PVA”)—a recently formed majority-owned subsidiary of PUF—to construct a one million square foot greenhouse operation, with large-scale manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products. MYM will own 35% of the Northern Rivers Project, which, at full scale, will have the capacity to produce 100,000 kilograms of high quality cannabis per year, worth between C$800 million and C$1.1 billion (based on current pricing metrics in the Australian cannabis marketplace). Australia has introduced progressive medical cannabis laws in the past few years, and are essentially where Canada was four years ago. Assuming recreational cannabis becomes legal and with a population of more than 24 million people, it is estimated that the cannabis market in Australia will grow to C$9 billion over the next 7 years making it a very attractive market. Being...

Read More

General Cannabis Announces Closing of Private Financing and Preliminary Third Quarter Revenue

DENVER, Oct. 10, 2017 (GLOBE NEWSWIRE) — General Cannabis Corp. (OTCQB:CANN), the comprehensive national resource to the regulated cannabis industry, today announced the closing of a private placement financing resulting in $725,000 of cash and cancellation of $25,000 of debt. The financing consisted of units sold at a price of $1.00 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $0.50 per share exercisable immediately through October 9, 2019.  At closing, the Company issued an aggregate of 750,000 shares of common stock and warrants to purchase up to 750,000 shares of common stock. General Cannabis also reported today its preliminary unaudited 2017 third quarter revenue of approximately $980,000, an increase of approximately 17% compared to the same period in 2016, driven by growth in our operations consulting and products segment. Estimated 2017 third quarter revenue increased by 15% compared to the second quarter of 2017, due primarily to organic growth in our security segment, as well as the acquisition of Mile High Protection Services. We also expect to have our highest level of quarterly revenue since inception. “We continue to focus on the profitability of our operating segments as we expand on a national scale,” said Robert Frichtel, Chief Executive Officer of General Cannabis. “The capital raise gives us the necessary...

Read More

Hydropothecary Receives Expanded Cannabis Storage Licence

GATINEAU, QC–(Marketwired – October 17, 2017) – The Hydropothecary Corporation (TSX VENTURE: THCX) (“THCX” or the “Company”) is pleased to announce that Health Canada has granted a licence amendment more than doubling its current licensed storage capacity. The Company’s current licensed capacity has been increased from 4,380 kg to 9,380 kg. The Company is also planning to construct additional vault space to meet the storage requirements anticipated as part of its 250,000 sq ft greenhouse expansion. With the expansion, the Company production capacity is expected to increase to 25,000 kg of dried cannabis per year. On June 22, 2017, Hydropothecary was granted an unlimited licence to produce and sell as much medical marijuana, oils, plants or seeds, as it can store. “This increase in our licensed storage capacity, when accompanied by our unlimited licence to produce and sell medical marijuana, puts us in a position to provide a consistent supply of high quality cannabis for both the medical and anticipated legal adult use markets,” said Sebastien St-Louis, CEO and co-founder. About The Hydropothecary Corporation The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides sun grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary’s branding, cannabis product offering, patient service standards and product pricing are consistent with THCX’s positioning...

Read More